Clearmind Medicine Inc. (CMND), a clinical-stage neuroplastogen pharmaceutical biotech company, announced that it is continuing participant enrollment for the third cohort of its ongoing Phase I/IIa clinical trial evaluating CMND-100, its investigational drug candidate for the treatment of Alcohol Use Disorder (AUD).
This enrollment follows the positive safety topline results from the second cohort evaluating CMND-100 in AUD reported earlier in February 2026.
CMND-100 is Clearmind's proprietary non-hallucinogenic oral drug candidate for the treatment of Alcohol Use Disorder (AUD).
The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD.
In the second cohort, CMND-100 demonstrated continued safety and tolerability, building on the favourable outcomes from prior cohorts.
Participant recruitment for the third cohort is happening at sites, including Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Centre.
"We are excited to progress with the clinical trial at these prestigious institutions", said Dr Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine.
CMND has traded between $0.8950 and $52.40 in the last year. The stock closed Wednesday's trade at $0.93, down 6.28%
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.